DexCom Inc (DXCM)vsEnovis Corp (ENOV)
DXCM
DexCom Inc
$83.03
-1.75%
HEALTHCARE · Cap: $31.90B
ENOV
Enovis Corp
$19.28
+4.73%
HEALTHCARE · Cap: $1.07B
Smart Verdict
WallStSmart Research — data-driven comparison
DexCom Inc generates 116% more annual revenue ($4.97B vs $2.30B). DXCM leads profitability with a 20.1% profit margin vs -48.0%. DXCM appears more attractively valued with a PEG of 1.35. DXCM earns a higher WallStSmart Score of 74/100 (B).
DXCM
Strong Buy74
out of 100
Grade: B
ENOV
Buy55
out of 100
Grade: C
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for DXCM.
Margin of Safety
+34.6%
Fair Value
$34.86
Current Price
$19.28
$15.58 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Every $100 of equity generates 38 in profit
Keeps 20 of every $100 in revenue as profit
Strong operational efficiency at 24.3%
Earnings expanding 43.6% YoY
Reasonable price relative to book value
Earnings expanding 153.1% YoY
Areas to Watch
Premium valuation, high expectations priced in
Trading at 11.9x book value
Expensive relative to growth rate
3.2% revenue growth
Smaller company, higher risk/reward
Operating margin of 4.2%
Comparative Analysis Report
WallStSmart ResearchBull Case : DXCM
The strongest argument for DXCM centers on Return on Equity, Profit Margin, Operating Margin. Profitability is solid with margins at 20.1% and operating margin at 24.3%. Revenue growth of 13.1% demonstrates continued momentum.
Bull Case : ENOV
The strongest argument for ENOV centers on Price/Book, EPS Growth.
Bear Case : DXCM
The primary concerns for DXCM are P/E Ratio, Price/Book.
Bear Case : ENOV
The primary concerns for ENOV are PEG Ratio, Revenue Growth, Market Cap.
Key Dynamics to Monitor
DXCM profiles as a mature stock while ENOV is a turnaround play — different risk/reward profiles.
ENOV carries more volatility with a beta of 1.43 — expect wider price swings.
DXCM is growing revenue faster at 13.1% — sustainability is the question.
DXCM generates stronger free cash flow (185M), providing more financial flexibility.
Bottom Line
DXCM scores higher overall (74/100 vs 55/100), backed by strong 20.1% margins and 13.1% revenue growth. ENOV offers better value entry with a 34.6% margin of safety. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
DexCom Inc
HEALTHCARE · MEDICAL DEVICES · USA
DexCom, Inc. is a company that develops, manufactures, and distributes continuous glucose monitoring (CGM) systems for diabetes management. It operates internationally with headquarters in San Diego, California, and has a manufacturing facility in Mesa, Arizona.
Enovis Corp
HEALTHCARE · MEDICAL DEVICES · USA
Enovis Corporation is a global medical technology company. The company is headquartered in Wilmington, Delaware.
Compare with Other MEDICAL DEVICES Stocks
Want to dig deeper into these stocks?